Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
InGeneron logo — Unlocking Regenerative Cell Therapy

InGeneron

Unlocking Regenerative Cell Therapy

Founded 2006 United States Houston, United States 18 employees Venture round Total: $52.75M Biotechnology, Health Care +1

General Information

Company Name InGeneron
Founded Year 2006
Location United States Houston, United States
Founders / Decision Makers
Team member
Employees 18
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with InGeneron. To contact InGeneron, visit ingeneron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does InGeneron compare?

A PDF of InGeneron and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting InGeneron soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About InGeneron

InGeneron is a clinical-stage biotechnology company that aims to revolutionize healthcare with its novel, safe, and evidence-based cell therapies. The company's mission revolves around unlocking the healing potential of each patient’s own regenerative cells processed at the point of care to enable same-day treatment, thus setting new therapeutic standards. Founded in 2006, InGeneron is currently focused on addressing orthopedic conditions and is actively engaged in multiple clinical trials to validate its technology as a disease-modifying treatment. With more than 20 years of research backing its work, InGeneron is committed to developing therapies supported by clinical evidence and approved by the FDA. Its recent $1.75M Venture Round investment on 01 March 2024 underscores investor confidence in the company's potential. As a company in the biotechnology and healthcare industries, InGeneron holds the promise to significantly impact the future landscape of regenerative medicine.

Business keywords: Regenerative cell therapy, Clinical-stage biotechnology, Orthopedic conditions, Minimally invasive treatments, Cell therapy product platform, Stem and regenerative cell research, Autologous adult stem cells, FDA-approved therapies, Healthcare innovation, Point-of-care treatments

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $1.75M -
01 Mar 2024
Series D $23.00M 1
Sanford Health
11 Jun 2019
Venture Round $3.50M -
05 Apr 2019
Series D $20.00M 1
Sanford Health
06 Mar 2017
Venture Round $4.50M -
05 Oct 2015

InGeneron Alternatives & Competitors

View All Alternatives
InGeneron vs
Lineage Cell Therapeutics
Lineage Cell Therapeutics United States

A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Post-IPO Equity
33 employees
Biopharma, Biotechnology
InGeneron vs
Cell BioEngines, Inc
Cell BioEngines, Inc United States

‘Off-the-Shelf’ Curative Cell Therapies

Pre-Seed
3 employees
Biotechnology, Health and Wellness
InGeneron vs
Notogen Inc.
Notogen Inc. Canada

Developing a disease-modifying regenerative therapy for degenerative disc disease

5 employees
Biotechnology, Health Care
View all alternatives

FAQ About InGeneron

Unlocking Regenerative Cell Therapy
InGeneron was founded in 2006.
InGeneron is headquartered in Houston, United States.
InGeneron operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Regenerative cell therapy, Clinical-stage biotechnology, Orthopedic conditions and Minimally invasive treatments.
InGeneron has approximately 18 employees.
InGeneron has completed 5 funding rounds, raising a total of $52.75M. The latest funding stage is Venture round.
Top alternatives and competitors to InGeneron include Lineage Cell Therapeutics, Cell BioEngines, Inc, Notogen Inc., Histocell. Regenerative Medicine, DiscGenics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InGeneron and Lineage Cell Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for InGeneron, https://bouncewatch.com/company/ingeneron, updated 30 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes